Preliminary Assessment of [18F]BL40 in PET/CT Scans

Not yet recruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

October 31, 2025

Conditions
Diffuse Large B-cell LymphomaMultiple MyelomaMantle Cell LymphomaMarginal Zone LymphomaChronic Lymphocytic LeukemiaWaldenström Macroglobulinemia
Interventions
DIAGNOSTIC_TEST

18F-BL40 PET/CT

Vital signs will be recorded prior to the BL40 injection. Each study subject will have an intravenous catheter inserted. Prior to the radiotracer injection an ultra low dose CT will be taken. Subjects are positioned supine, arms down. The subject will receive a bolus intravenous dose of the 18F-BL40 from an approved study supplier site. A Dynamic PET scan will be taken of the heart. Then a serial whole body PET scan will be done. Vital signs will be taken again and the subject will have a bathroom break. The patient will return to the scanner bed for a standard low dose CT and whole body PET scan. Vital signs will be taken again, and subject will be allowed to use the washroom again. The subject will return to the scanner bed for the final time for an ultra low dose CT and whole body PET scan. A final set of vitals will be taken and the subject will be discharged.

DIAGNOSTIC_TEST

18F-FDG PET/CT

"The patient will return on another day for the 18F-FDG PET/CT scan. A fasting period of 6 hours is required before this scan.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."

DIAGNOSTIC_TEST

Routine Blood Draw - Phase 1 only

Complete blood counts and routine clinical chemistry performed before and repeated within 18-72 hours after 18F-BL40 administration.

Trial Locations (1)

V5Z4E6

BC Cancer, Vancouver

All Listed Sponsors
lead

British Columbia Cancer Agency

OTHER

NCT06224309 - Preliminary Assessment of [18F]BL40 in PET/CT Scans | Biotech Hunter | Biotech Hunter